Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

The Road Less Traveled: SARS-CoV-2 and Cell-Mediated Immunity

Molecular Therapy(2020)10.1016/j.ymthe.2020.10.003Source: DataRank Database

The Road Less Traveled: SARS-CoV-2 and Cell-Mediated Immunity is a research paper published in Molecular Therapy (2020). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 0.02)OA: hybridTopics (58)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (1)

Kevin V. Morris ORCID

Live enrichment

PubMed:33053318 PMC:PMC7546259 OpenAlex:https://openalex.org/W3092256127

NIMH NIH HHS

Grant: R01 MH113407

NIMH NIH HHS

Grant: R01 113407-01

National Institutes of Health

Grant: 5R01MH113407-05

Transcriptional control, targeted modification, and excision of HIV in the brain

National Institutes of Health

FWCI

0.02

Citation Percentile

0.4%

Citation Trend

2021

hybridLicense: cc-by-nc-nd

journalhttp://www.cell.com/article/S1525001620305372/pdf

publisherhttp://www.cell.com/article/S1525001620305372/pdf

publisherhttps://api.elsevier.com/content/article/PII:S1525001620305372?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S1525001620305372?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.ymthe.2020.10.003

Fields of Study

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesAnimal Virus Infections Studies03 medical and health sciences0302 clinical medicineAntibodies, ViralCOVID-19HumansImmunity, CellularPandemicsRespiratory Distress SyndromeSARS-CoV-2Th1 CellsTh2 Cells

MeSH Terms

COVID-19SARS-CoV-2Antibodies, ViralHumansImmunity, CellularRespiratory Distress SyndromeTh1 CellsTh2 CellsPandemics

Keywords

AntibodyImmunityVirologyImmunologyCoronavirusVirusMouse hepatitis virusNeutralizing antibodyAntibody titerAntibody-dependent enhancementSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)TiterMedicineBiologyCoronavirus disease 2019 (COVID-19)DiseaseImmune systemViral replicationInfectious disease (medical specialty)Internal medicinePharmacologyImmunity, CellularRespiratory Distress SyndromeSARS-CoV-2COVID-19Th1 CellsAntibodies, ViralEditorialTh2 CellsDrug DiscoveryGeneticsMolecular MedicineHumansMolecular BiologyPandemics

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

The Road Less Traveled: SARS-CoV-2 and Cell-Mediated Immunity

FAIR Checklist

Authors (1)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)